Payment overview · 2025
General Payments
$2,299.16
122 reported records · 30 companies
Healthcare provider profile · identity verified
Munawar Haider, MD
Allopathic & Osteopathic Physicians|Family Medicine · BEDFORD, TX · NPI 1124018155
Verified facts
What the public records show
CMS Open Payments records show Munawar Haider, MD received $2,299.16 in general payments during 2025 across 122 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 10.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Briviact, Farxiga, Ingrezza, Jardiance, Kerendia, Mounjaro, Nurtec Odt, Ozempic, Paxlovid, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 349 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 349 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1394 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $247.22 | 10.8% | 11 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $226.34 | 9.8% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $174.95 | 7.6% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $168.19 | 7.3% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $156.32 | 6.8% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $122.71 | 5.3% | 5 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$106.83 | 4.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $97.88 | 4.3% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $91.07 | 4.0% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $80.40 | 3.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.29 | 3.5% | 4 | 2025 |
| Avvisto Therapeutics, LLC | Unresolved — no canonical attribution shown | $79.19 | 3.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $78.79 | 3.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $72.98 | 3.2% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $67.80 | 3.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $59.93 | 2.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.35 | 2.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.09 | 1.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.81 | 1.8% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $39.30 | 1.7% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $29.26 | 1.3% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $27.33 | 1.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.95 | 1.0% | 1 | 2025 |
| Fidia Pharma USA Inc. | Unresolved — no canonical attribution shown | $22.18 | 1.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.01 | 0.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.70 | 0.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.00 | 0.8% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $17.98 | 0.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.04 | 0.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.27 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,278.94 | 121 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $226.34 | 11 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $221.59 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $168.19 | 14 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $153.27 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $122.71 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $118.27 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $105.77 | 6 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $80.40 | 3 | 2025 |
Source payment records
|
|||||
| CYCLOSET Normalized: cycloset |
Drug | Avvisto Therapeutics, LLC | $79.19 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $78.79 | 4 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $67.80 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $63.90 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $50.55 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $49.91 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.97 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $45.87 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $41.09 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.46 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.46 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $39.30 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.02 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $29.26 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $27.33 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $25.63 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| HYMOVIS Normalized: hymovis |
Device | Fidia Pharma USA Inc. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| TRILURON Normalized: triluron |
Device | Fidia Pharma USA Inc. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $12.57 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 35 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 150 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 349 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 129 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 19 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
224 | 40 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
150 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
51 | 21 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
349 | 70 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
349 | 70 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
157 | 30 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
93 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
129 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
35 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1394 | 172 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 18 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2285 | 531 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1629 | 331 |
| Eliquis | Apixaban | 1394 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 1349 | 326 |
| Gabapentin | Gabapentin | 1261 | 276 |
| Furosemide | Furosemide | 1056 | 261 |
| Potassium Chloride | Potassium Chloride | 1034 | 230 |
| Omeprazole | Omeprazole | 944 | 251 |
| Trazodone Hcl | Trazodone Hcl | 906 | 205 |
| Sertraline Hcl | Sertraline Hcl | 830 | 163 |
| Tamsulosin Hcl | Tamsulosin Hcl | 778 | 176 |
| Donepezil Hcl | Donepezil Hcl | 774 | 163 |
| Mirtazapine | Mirtazapine | 729 | 142 |
| Lisinopril | Lisinopril | 728 | 174 |
| Pantoprazole Sodium | Pantoprazole Sodium | 713 | 189 |
| Losartan Potassium | Losartan Potassium | 690 | 183 |
| Metoprolol Tartrate | Metoprolol Tartrate | 645 | 157 |
| Metformin Hcl | Metformin Hcl | 598 | 138 |
| Montelukast Sodium | Montelukast Sodium | 590 | 146 |
| Famotidine | Famotidine | 570 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 569 | 142 |
| Tramadol Hcl | Tramadol Hcl | 545 | 135 |
| Carvedilol | Carvedilol | 544 | 142 |
| Duloxetine Hcl | Duloxetine Hcl | 539 | 121 |
| Clopidogrel | Clopidogrel Bisulfate | 500 | 116 |
| Memantine Hcl | Memantine Hcl | 500 | 109 |
| Divalproex Sodium | Divalproex Sodium | 497 | 106 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 458 | 85 |
| Levetiracetam | Levetiracetam | 413 | 66 |
| Buspirone Hcl | Buspirone Hcl | 397 | 101 |
| Hydralazine Hcl | Hydralazine Hcl | 394 | 94 |
| Fluticasone Propionate | Fluticasone Propionate | 380 | 136 |
| Escitalopram Oxalate | Escitalopram Oxalate | 372 | 91 |
| Januvia | Sitagliptin Phosphate | 368 | 47 |
| Jardiance | Empagliflozin | 349 | 70 |
| Simvastatin | Simvastatin | 319 | 86 |
| Alprazolam | Alprazolam | 305 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 300 | 96 |
| Prednisone | Prednisone | 295 | 147 |
| Spironolactone | Spironolactone | 286 | 60 |
| Allopurinol | Allopurinol | 280 | 60 |
| Gemtesa | Vibegron | 275 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 267 | 133 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 261 | 110 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 256 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 253 | 62 |
| Xarelto | Rivaroxaban | 252 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 246 | 61 |
| Pregabalin | Pregabalin | 241 | 48 |
| Baclofen | Baclofen | 240 | 47 |
| Myrbetriq | Mirabegron | 224 | 40 |
| Glimepiride | Glimepiride | 222 | 73 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 218 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 216 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 212 | 88 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 212 | 62 |
| Metformin Hcl Er | Metformin Hcl | 204 | 53 |
| Methocarbamol | Methocarbamol | 199 | 68 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 198 | 48 |
| Celecoxib | Celecoxib | 192 | 61 |
| Doxycycline Hyclate | Doxycycline Hyclate | 185 | 102 |
| Latanoprost | Latanoprost | 185 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 51 |
| Enulose | Lactulose | 180 | 42 |
| Alendronate Sodium | Alendronate Sodium | 179 | 60 |
| Amiodarone Hcl | Amiodarone Hcl | 179 | 41 |
| Midodrine Hcl | Midodrine Hcl | 176 | 59 |
| Diclofenac Sodium | Diclofenac Sodium | 175 | 59 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 174 | 63 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 173 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 169 | 31 |
| Finasteride | Finasteride | 165 | 41 |
| Meloxicam | Meloxicam | 162 | 44 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 162 | 97 |
| Torsemide | Torsemide | 158 | 49 |
| Clonidine Hcl | Clonidine Hcl | 157 | 82 |
| Trulicity | Dulaglutide | 157 | 30 |
| Sodium Chloride | 0.9 % Sodium Chloride | 155 | 71 |
| Sucralfate | Sucralfate | 151 | 27 |
| Farxiga | Dapagliflozin Propanediol | 150 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 150 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 147 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 145 | 51 |
| Oxybutynin Chloride | Oxybutynin Chloride | 145 | 52 |
| Lorazepam | Lorazepam | 139 | 46 |
| Fluoxetine Hcl | Fluoxetine Hcl | 138 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 138 | 85 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 137 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 133 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 132 | 33 |
| Humalog Kwikpen U-100 | Insulin Lispro | 131 | 46 |
| Azithromycin | Azithromycin | 130 | 88 |
| Ozempic | Semaglutide | 129 | 27 |
| Primidone | Primidone | 124 | 27 |
| Clonazepam | Clonazepam | 120 | 27 |
| Atenolol | Atenolol | 118 | 25 |
| Levofloxacin | Levofloxacin | 115 | 66 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 112 | 65 |
| Warfarin Sodium | Warfarin Sodium | 112 | 18 |
| Glipizide | Glipizide | 109 | 29 |
| Budesonide | Budesonide | 107 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 105 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 105 | 27 |
| Tradjenta | Linagliptin | 105 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 104 | 13 |
| Lamotrigine | Lamotrigine | 103 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 25 |
| Nifedipine Er | Nifedipine | 102 | 35 |
| Albuterol Sulfate | Albuterol Sulfate | 101 | 33 |
| Risperidone | Risperidone | 100 | 17 |
| Ezetimibe | Ezetimibe | 99 | 27 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 99 | 22 |
| Oxcarbazepine | Oxcarbazepine | 96 | 17 |
| Propranolol Hcl | Propranolol Hcl | 95 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 94 | 42 |
| Entresto | Sacubitril/Valsartan | 93 | 11 |
| Ondansetron Odt | Ondansetron | 93 | 38 |
| Lactulose | Lactulose | 92 | 42 |
| Brimonidine Tartrate | Brimonidine Tartrate | 87 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 83 | 64 |
| Cephalexin | Cephalexin | 83 | 46 |
| Topiramate | Topiramate | 83 | 15 |
| Folic Acid | Folic Acid | 80 | 20 |
| Tresiba Flextouch U-100 | Insulin Degludec | 78 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 76 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 75 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 75 | 12 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 75 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 74 | 49 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 74 | suppressed |
| Lubiprostone | Lubiprostone | 74 | 18 |
| Megestrol Acetate | Megestrol Acetate | 73 | 33 |
| Breo Ellipta | Fluticasone/Vilanterol | 72 | 18 |
| Bumetanide | Bumetanide | 71 | 15 |
| Bupropion Xl | Bupropion Hcl | 71 | 27 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 70 | 30 |
| Levemir Flexpen | Insulin Detemir | 70 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 20 |
| Linzess | Linaclotide | 68 | 15 |
| Meclizine Hcl | Meclizine Hcl | 68 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 67 | 21 |
| Estradiol | Estradiol | 66 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | suppressed |
| Eszopiclone | Eszopiclone | 64 | 15 |
| Lacosamide | Lacosamide | 64 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 64 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 62 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 61 | 38 |
| Cefdinir | Cefdinir | 60 | 46 |
| Fenofibrate | Fenofibrate,micronized | 60 | 19 |
| Fluconazole | Fluconazole | 60 | 43 |
| Ramelteon | Ramelteon | 60 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 59 | 38 |
| Olanzapine | Olanzapine | 58 | 18 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 57 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 57 | 14 |
| Carisoprodol | Carisoprodol | 57 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 16 |
| Fenofibrate | Fenofibrate | 56 | 20 |
| Lovastatin | Lovastatin | 56 | 14 |
| Konvomep | Omeprazole/Sodium Bicarbonate | 55 | suppressed |
| Metolazone | Metolazone | 55 | 18 |
| Scopolamine | Scopolamine | 55 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 54 | 13 |
| Promethazine Hcl | Promethazine Hcl | 54 | 33 |
| Rivastigmine | Rivastigmine | 54 | suppressed |
| Nitroglycerin | Nitroglycerin | 53 | 38 |
| Sevelamer Carbonate | Sevelamer Carbonate | 53 | 11 |
| Aripiprazole | Aripiprazole | 52 | 16 |
| Glipizide Er | Glipizide | 52 | suppressed |
| Xifaxan | Rifaximin | 52 | suppressed |
| Calcitriol | Calcitriol | 51 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 51 | 21 |
| Temazepam | Temazepam | 51 | 11 |
| Anastrozole | Anastrozole | 50 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 50 | 26 |
| Methotrexate | Methotrexate Sodium | 50 | suppressed |
| Naproxen | Naproxen | 50 | 16 |
| Permethrin | Permethrin | 50 | 44 |
| Azelastine Hcl | Azelastine Hcl | 49 | 23 |
| Nyamyc | Nystatin | 49 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 48 | 24 |
| Nystatin | Nystatin | 48 | 29 |
| Clobetasol Propionate | Clobetasol Propionate | 47 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | 17 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 45 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 13 |
| Ranolazine Er | Ranolazine | 44 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 44 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 43 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 42 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 41 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 19 |
| Digoxin | Digoxin | 41 | 16 |
| Levemir | Insulin Detemir | 41 | suppressed |
| Timolol Maleate | Timolol Maleate | 41 | 13 |
| Cefepime Hcl | Cefepime Hcl | 40 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 40 | 18 |
| Synjardy | Empagliflozin/Metformin Hcl | 40 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 39 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 38 | suppressed |
| Lidocaine | Lidocaine | 37 | 14 |
| Meropenem | Meropenem | 37 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 18 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 36 | 16 |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 35 | 35 |
| Diazepam | Diazepam | 35 | 12 |
| Humalog | Insulin Lispro | 35 | 14 |
| Ibuprofen | Ibuprofen | 35 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | 12 |
| Mupirocin | Mupirocin | 35 | 24 |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 34 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 34 | suppressed |
| Carbamazepine | Carbamazepine | 33 | suppressed |
| Fentanyl | Fentanyl | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 18 |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 17 |
| Arformoterol Tartrate | Arformoterol Tartrate | 32 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 32 | suppressed |
| Latuda | Lurasidone Hcl | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 13 |
| Daptomycin | Daptomycin | 31 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 31 | suppressed |
| Ampicillin-Sulbactam | Ampicillin Sod/Sulbactam Sod | 30 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 30 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 30 | suppressed |
| Acyclovir | Acyclovir | 29 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 29 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 29 | suppressed |
| Nystop | Nystatin | 29 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 29 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 29 | 11 |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Ivermectin | Ivermectin | 28 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Movantik | Naloxegol Oxalate | 26 | suppressed |
| Phenytoin | Phenytoin | 26 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 26 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 25 | suppressed |
| Lamotrigine Odt | Lamotrigine | 25 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 25 | suppressed |
| Acetazolamide | Acetazolamide | 24 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 19 |
| Briviact | Brivaracetam | 23 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 23 | suppressed |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 22 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 22 | 22 |
| Valsartan | Valsartan | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Insulin Lispro | Insulin Lispro | 21 | 14 |
| Ketoconazole | Ketoconazole | 21 | 13 |
| Lanthanum Carbonate | Lanthanum Carbonate | 21 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 21 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 21 | 17 |
| Sevelamer Hcl | Sevelamer Hcl | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Dexamethasone | Dexamethasone | 20 | 15 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Austedo | Deutetrabenazine | 19 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 19 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 19 | suppressed |
| Entacapone | Entacapone | 19 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 19 | suppressed |
| Mirabegron Er | Mirabegron | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 18 |
| Prednisolone Acetate | Prednisolone Acetate | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | 15 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | 13 |
| Lurasidone Hcl | Lurasidone Hcl | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 17 | suppressed |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | 12 |
| Dorzolamide Hcl | Dorzolamide Hcl | 16 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Letrozole | Letrozole | 16 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Erythromycin | Erythromycin Base | 15 | 11 |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Mesalamine | Mesalamine | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Procrit | Epoetin Alfa | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Ertapenem | Ertapenem Sodium | 14 | suppressed |
| Fetroja | Cefiderocol Sulfate Tosylate | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Belbuca | Buprenorphine Hcl | 13 | suppressed |
| Epogen | Epoetin Alfa | 13 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | 11 |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Rhopressa | Netarsudil Mesylate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,299.16 · 122 records | Teva Pharmaceuticals USA, Inc. | ABRYSVO, AIRSUPRA, AUSTEDO XR, Briviact, CAPLYTA, CAPVAXIVE, CYCLOSET, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GVOKE HYPOPEN, HYMOVIS, Hillrom - Vest System Model 105 Home Care, INGREZZA, JARDIANCE, KISUNLA, Kerendia, LEQVIO, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, REPATHA, REXULTI, Rybelsus, Senza, Sunosi, TRILURON, The Cologuard Plus Collection Kit, UZEDY, VERQUVO, VRAYLAR, Veozah, XYOSTED, ZEPBOUND, ZORYVE | 26 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error